Serum concentrations of citalopram - Dose-dependent variation in R- and S-enantiomer ratios

Pharmacopsychiatry

Volumn 43, Issue 5, 2010, Pages 190-193

  Tanum, L ^a   Strand, L P ^a   Refsum, H ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ENANTIOMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; BLOOD; CHEMISTRY; DRUG MONITORING; MIDDLE AGED; STEREOISOMERISM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; YOUNG ADULT;

EID: 77954885807     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0030-1254106     Document Type: Article

References (30)

1. Auquier P, Robitail S, Llorca PM, et al. Comparison of escitalopram and citalopram efficacy: a meta- analysis. Int J Psychiatry Clin Pract 2003 7 259-268
2. Baker GB, Coutts RT, Holt A. Metabolism and chirality in Psychopharmacology. Biol Psychiatry 1994 36 211-213
3. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995 6 287-295
4. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. Ther Drug Monit 2004 26 145-151
5. Burke WJ, Gergel I, Anjana B. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 63 331-336
6. Caldwell J, Wainer IW. Stereochemistry: definition and a note on nomenclature. Hum Psychopharmacol Clin Exp 2001 16 S105-S107
7. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986 90 131-138
8. Dufour H, Bouchacourt M, Thermoz P, et al. Citalopram a highly selective 5-HT uptake inhibitor in the treatment of depressed patients. lnt Clin Psychopharmacol 1987 2 225-237
9. El Mansari M, Wiborg O, Mnie-Filali O, et al. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: In-vitro and in-vivo studies. Int J Neuropsychopharmacol 2007 10 31-40
10. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002 7 40-44
11. Hogg S, Sanchez C. The antidepressant effects of citalopram are mediated by the S-((+))- and not the R-() enantiomer. Eur Neuropsychopharmacol 1999 9 S213
12. Hyttel J. Citalopram Pharmacological profile of specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982 6 277-295
13. Hyttel J, Bøgesø KP, Perregaard J, et al. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm 1992 88 157-160
14. Kasper S, Sacher J, Klein, et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009 24 119-125
15. Kosel M, Amey M, Aubert A-C, et al. In vitro metabolism of citalopram by monoamine oxidase B in human blood. Eur Neuropsychopharmacol 2001 11 75-78
16. Kosel M, Gnerre C, Voirol P, et al. In vitro biotransformation of the selective serotonin reuptake inhibitor, citalopram, its enantiomers and demethylated metabolites by monoamine oxidase in rat and human brain preparations. Mol Psychiatry 2002 7 181-188
17. Le Bloc'h Y, Woggon B, Weissenrieder H, et al. Routine therapeutic drug monitoring in patients treated with 10360mg/day Citalopram. Ther Drug Monit 2003 25 600-608
18. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004 19 149-155
19. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005 59 268-274
20. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 20 131-137
21. Nikisch G, Mathe AA, Czernik A, et al. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressed patients. J Clin Psychopharmacol 2004 24 283-290
22. Rasmussen B, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000 22 143-154
23. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997 7 1-10
24. Rochat B, Kosel M, Boss G, et al. Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidase in human liver. Biochem Pharmacol 1998 56 15-23
25. Sanchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004 174 163-176
26. Sidhu J, Priskorn M, Poulsen M, et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 1997 9 686-692
27. Totah RA, Allen KE, Sheffels P, et al. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. JPET 2007 321 389-399
28. Uhr M, Grauer MT. abcb1 ab P-Glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003 37 179-185
29. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citaopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 29 1102-1109
30. Zhong H, Hansen KB, Boyle NJ, et al. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 2009 462 207-212